Breaking Down Crocs: 11 Analysts Share Their Views
In the last three months, 11 analysts have published ratings on Crocs (NASDAQ:CROX), offering a diverse range of…
What 5 Analyst Ratings Have To Say About LendingTree
LendingTree (NASDAQ:TREE) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events matching the placebo.
10 Analysts Assess Genmab: What You Need To Know
Analysts’ ratings for Genmab (NASDAQ:GMAB) over the last quarter vary from bullish to bearish, as provided by 10…
Arbor Realty Trust Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
5 analysts have shared their evaluations of Arbor Realty Trust (NYSE:ABR) during the recent three months, expressing a…
Jabil Reiterated FY24 Revenue of $28.5B Vs $28.49B Est, Adj EPS of $8.40 Vs $8.37 Est
Fiscal Year 2024 Outlook:
• Net revenue
$28.5 billion
• Core operating margin
Jabil Expects Q4 Revenue of $6.3B-$6.9B Vs $6.8B Est, Adj EPS of $2.03-$2.43 Vs $2.22 Est
Fourth Quarter of Fiscal Year 2024 Outlook:
• Net revenue
$6.3 billion to $6.9 billion
• U.S. GAAP operating
Limiting ‘Apple Intelligence’ Features Not A Tactic To Boost iPhone Sales, Say Top Executives: ‘We Would’ve Been Smart Enough Just To Do Our Most Recent iPads And Macs, Too’
This has sparked concerns about a possible attempt by Apple to boost the sales of its more expensive iPhones.
EXCLUSIVE: Will The Crypto Bulls Come Back In the Fall? Experts Explain Why Summers Are Not The Best For Bitcoin, Ethereum And Other Coins
"Sell in May and Walk Away." This age-old Wall Street adage, in addition to the stock market, has proven increasingly applicable to cryptocurrencies as well.
From June to August, market growth and trading volumes have historically trended down across the sector.
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication.